samedan logo
 
 
spacer
home > pmps > winter 2002 > containment solutions: solids charging into process vessels
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Containment Solutions: Solids Charging into Process Vessels

Vessel charging in the process plant has long been identified as a major source of dust emission. Now, with increasing use of active pharmaceutical ingredients (APIs) in the processing and manufacturing stages, the need for assured operator protection is increasing the requirement for effective dust containment. The maximum permissible operator exposure level (OEL) considered in this article is 10µg/m3.

What are the Available Options?

Containment during vessel charging falls into two key categories:


Read full article >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Martyn Ryder, Managing Director of Extract Technology
Martyn Ryder is the Managing Director of Extract Technology, part of the Carlisle Life Science Group. He was educated at Leeds Polytechnic in HVAC and Building Services.

In 1981 he founded Extract Technology, a supplier of pharmaceutical dust control and high containment systems, based in Huddersfield, UK.

spacer
Martyn Ryder
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

4th Annual Patient Recruitment and Retention in Clinical Trials

13-15 October 2008, Amsterdam

Patient recruitment is now consuming thirty percent of clinical trial time - more time than any other clinical trial activity - and almost half of all trial delays result from patient recruitment problems. As the recruiting culture becomes more sophisticated and the forces affecting patient enrollment grow more numerous and complex, pharmaceutical companies are striving to discover new strategies to facilitate enrollment in clinical trials. With increasing industry pressure to develop, test and market greater numbers of new drugs faster, pharmaceutical companies need to perform clinical trials as quickly as possible. Inefficient patient recruitment processes is a formidable barrier to pharmaceutical companies' success in launching new products. Improving the patient recruitment process is imperative to avoid wasted investments and eliminate costly delays in bringing new drugs to market -- today and even more so in the not-so-distant future. Improved patient recruitment presents one of the largest opportunities for pharmaceutical companies to eliminate delays in clinical trials, thereby making it possible to reduce time to market.  With patent time limits and large overheads meaning that any delays in the development timeline can be disastrous, a good understanding of how to successfully recruit patients for trials is vital for any company looking to succeed.
More info >>

 
News and Press Releases

“PACK DIFFERENT” with EMBALLAGE 2008

“Business, Innovation, Outlook” are the watchwords for the 38th World Packaging Exhibition which opens in Paris from 17 to 21 November 2008. Fifteen months before the key packaging event of the end of 2008, EMBALLAGE displays its differences to offer you a new edition that is even more representative, international and rich in new features.
More info >>

 

©2000-2007 Samedan Ltd.
About Us | Register | Login | Site Map | Terms and Conditions | Contact Us |
Add to favourites

Print this page

Send to a friend
Privacy statement